PTSD

FDA Greenlights MDMA Studies for Posttraumatic Stress Disorder

By August 31, 2017

"Our Phase 2 data was extremely promising with a large effect size, and we are ready to move forward quickly," said Amy Emerson, Executive Director of the MAPS Public Benefit Corporation.